Modality
ASO
MOA
TNFi
Target
HER2
Pathway
Lipid Met
Psoriasis
Development Pipeline
Preclinical
~Mar 2015
→ ~Jun 2016
Phase 1
~Sep 2016
→ ~Dec 2017
Phase 2
Mar 2018
→ Dec 2029
Phase 2Current
NCT07059649
1,324 pts·Psoriasis
2019-06→2027-09·Active
NCT07016460
2,597 pts·Psoriasis
2018-03→2029-12·Recruiting
3,921 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-09-161.5y awayPh2 Data· Psoriasis
2029-12-253.7y awayPh2 Data· Psoriasis
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2
Recruit…
P2
Active
Catalysts
Ph2 Data
2027-09-16 · 1.5y away
Psoriasis
Ph2 Data
2029-12-25 · 3.7y away
Psoriasis
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07059649 | Phase 2 | Psoriasis | Active | 1324 | Safety |
| NCT07016460 | Phase 2 | Psoriasis | Recruiting | 2597 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| ELV-1411 | Enliven | NDA/BLA | HER2 | |
| Rimatinib | Ventyx Bio | Phase 1 | CD20 |